Financial Performance - Net revenue for Q3 2025 was $375.3 million, a decrease of 1.2% compared to Q3 2024[5] - GAAP net loss was $20.1 million, compared to a net income of $37.6 million in the same quarter last year[8] - Total net revenues for the quarter ended September 28, 2025, were $375.3 million, a decrease of 1.5% compared to $379.9 million for the same quarter in 2024[27] - For the quarter ended September 28, 2025, Krispy Kreme reported a net loss of $20.1 million compared to a net income of $37.6 million for the same quarter in 2024[39] - The company experienced a total net revenue decline of $131.1 million or 10.4% for the first three quarters of fiscal 2025 compared to the same period in 2024[42] Adjusted EBITDA - Adjusted EBITDA increased by 17% to $40.6 million, with an adjusted EBITDA margin of 10.8%, up from 9.1%[9] - Adjusted EBITDA for the quarter was $40,597 thousand, representing an increase from $34,699 thousand in the prior year, reflecting a growth of approximately 23%[37] - The U.S. segment's Adjusted EBITDA increased to $21,010 thousand from $13,922 thousand year-over-year, marking a growth of about 51%[38] - International segment Adjusted EBITDA was $23,157 thousand, slightly up from $22,779 thousand, indicating a growth of approximately 2%[38] Revenue Segments - U.S. segment net revenue declined by $12.2 million to $216.2 million, a decrease of approximately 5.3%[11] - International segment net revenue grew by $9.5 million, or approximately 7.3%, with organic revenue growth of 6.2%[13] - U.S. revenues decreased by 5.3% to $216.2 million in Q3 2025 from $228.4 million in Q3 2024, while international revenues increased by 7.3% to $140.2 million[42] - Organic revenue increased by $2.2 million, or approximately 0.6%, driven by growth in the International segment[7] - Organic revenue growth for the third quarter of fiscal 2025 was 0.6%, with U.S. organic revenue declining by 2.2% and international organic revenue growing by 6.2%[42] Cash Flow and Liquidity - Cash provided by operating activities was $42.3 million, resulting in free cash flow of $15.5 million[3] - Net cash provided by operating activities for the quarter was $42,282 thousand, a substantial increase from $3,262 thousand in the same quarter last year[31] - Free cash flow for the quarter was $15,544 thousand, contrasting with a negative free cash flow of $(22,880) thousand in the prior year[31] - Total available liquidity as of September 28, 2025, was $215.2 million, including $30.7 million in cash[17] Assets and Liabilities - Total assets decreased to $2.6 billion as of September 28, 2025, down from $3.1 billion as of December 29, 2024[29] - Current liabilities totaled $448.9 million, a decrease from $486.2 million at the end of the previous fiscal year[29] - The company’s long-term debt, less current portion, increased to $906.2 million from $844.5 million[29] - Net debt increased to $951,995,000 as of September 28, 2025, compared to $875,263,000 as of December 29, 2024, reflecting a rise of 8.7%[50] - The total long-term debt, including debt issuance costs, rose to $979,463,000 as of September 28, 2025, compared to $900,903,000 as of December 29, 2024, an increase of 8.7%[50] Impairment Charges - The company experienced a significant impairment charge of $411.9 million related to goodwill and other assets[27] - The company experienced a significant goodwill impairment of $355,958 thousand during the three quarters ended September 28, 2025[31] - The company reported a goodwill impairment of $356.0 million for the three quarters ended September 28, 2025[39] Operational Metrics - Global Points of Access decreased by 960, or 6.1%, to 14,851 due to strategic closures of unprofitable locations[3] - Total Global Points of Access decreased to 14,851 in Q3 2025 from 15,811 in Q3 2024, a decline of 6.1%[46] - The total number of U.S. DFD Doors decreased to 6,971 in Q3 2025 from 7,711 in Q3 2024, a reduction of 9.6%[46] - Total Hot Light Theater Shops in the U.S. remained stable at 235 in Q3 2025 compared to 236 in Q3 2024[46] - International Hot Light Theater Shops increased to 52 in Q3 2025 from 48 in Q3 2024, a growth of 8.3%[46] - Total Hubs decreased slightly to 421 in Q3 2025 from 423 in Q3 2024, a decline of 0.5%[48] - The number of Fresh Shops in the U.S. decreased to 69 in Q3 2025 from 71 in Q3 2024, a decline of 2.8%[46] - The total number of Fresh Shops globally increased to 1,718 in Q3 2025 from 1,638 in Q3 2024, a growth of 4.9%[46] Cybersecurity Costs - The company incurred $1.5 million in costs related to the remediation of a cybersecurity incident during the quarter ended September 28, 2025[40]

Financial Performance - Total revenue for Q3 2025 was $2.11 billion, a decrease of 5.4% year over year[6] - Net loss attributable to stockholders was $1,625.9 million, or $(3.47) per share, including a non-cash impairment charge of approximately $1.6 billion[6] - Adjusted EBITDA for Q3 2025 was $830.7 million, down 3.6% year over year, with a margin of 39.4%[6] - Total revenue for Q3 2025 was $2,108,110, a decrease of 5.4% compared to $2,227,700 in Q3 2024[17] - Broadband revenue decreased to $873,449 in Q3 2025 from $913,417 in Q3 2024, a decline of 4.4%[17] - Net loss attributable to Altice USA stockholders for Q3 2025 was $1,625,899, compared to a net loss of $42,970 in Q3 2024[17] - Adjusted EBITDA for the nine months ended September 30, 2025, was $2,433,483, down from $2,575,708 in the same period of 2024, representing a decrease of 5.5%[24] - Operating income (loss) for Q3 2025 was $(1,164,784), compared to $444,593 in Q3 2024[17] - Free Cash Flow deficit was ($178.1) million, compared to a positive $76.9 million in Q3 2024[6] - Free Cash Flow (Deficit) for the nine months ended September 30, 2025, was $(318,267), compared to $99,504 in 2024[25] Subscriber Metrics - Total Broadband Primary Service Units (PSUs) experienced net losses of -58k, with total broadband subscribers ending at 4.2 million[6] - Fiber customer base reached 703k, a 46% increase compared to Q3 2024, with 23.0% penetration of the fiber network[11] - Mobile line net additions were +38k, with total mobile lines reaching 584k, a 39% increase year over year[11] Debt and Cash Position - Consolidated Net Debt for CSC Holdings, LLC as of September 30, 2025, is $22,890 million, with gross debt totaling $23,747 million[26] - The consolidated net debt for Altice USA is $25,351 million, with a total gross debt of $26,279 million[27] - The total cash position for CSC Holdings, LLC is $(857) million, while Cablevision Lightpath has cash of $(50) million[27] - Cash, cash equivalents, and restricted cash at the end of Q3 2025 totaled $1,043,664, an increase from $250,291 at the end of Q3 2024[18] Capital Expenditures - Capital expenditures for the nine months ended September 30, 2025, were $1,065,163, slightly higher than $1,042,975 in 2024[18] - The weighted average cost of debt (WACD) for CSC Holdings is 6.9%[27] Strategic Initiatives - The company plans to change its corporate name to Optimum Communications, Inc., effective November 7, 2025[10] - The company is focusing on operational efficiency, including workforce optimization and AI capabilities, as part of its 2025 priorities[33] - Revenue opportunities are targeted through broadband, mobile, and fiber growth, aiming to expand penetration of new and existing product offerings[33] - The company plans to enhance its network capabilities to deliver multi-gig speeds and expand its passings footprint[33] - The company is pursuing a sustainable capital structure, including capital structure transformation plans[33] - The company aims to achieve targets for Adjusted EBITDA and revenue through effective pricing and rate management strategies[33] - Future developments in the markets of interest are being closely monitored to adapt strategies accordingly[33] - The company is exploring strategic transactions, including its first-ever primarily HFC asset-backed loan[33] - Rebranding initiatives are underway, with anticipated benefits to enhance market presence[33] Market Conditions - There are expectations for macroeconomic conditions and consumer demand to influence subscriber and market share trends[33] - The company disclaims any obligation to update forward-looking statements, emphasizing the inherent risks and uncertainties involved[33] Operational Metrics - Gross margin reached an all-time high of 69.7%, supported by video gross margin expansion of approximately 350 basis points year over year[6] - The Adjusted EBITDA margin for Q3 2025 was 39.4%, compared to 38.7% in Q3 2024[24] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $746,896, down from $1,142,479 in 2024[18] - The service call rate and service visit rate are annualized metrics reflecting customer support needs[29] - The company has a capital intensity ratio that reflects total cash capital expenditures as a percentage of total revenue[29]

Financial Performance - Consolidated net sales for Q1 fiscal 2026 were $69.0 million, an increase of $3.6 million or 5.6% compared to the prior year[4] - Income from continuing operations was $3.7 million, or $0.22 per diluted share, up from $1.0 million, or $0.06 per diluted share in the prior-year period[7] - Adjusted Net Income for Q1 fiscal 2026 was $4.5 million, or $0.28 per diluted share, compared to $1.9 million, or $0.12 per diluted share in the prior-year period[7] - Adjusted EBITDA was $6.7 million, up $2.9 million from the prior-year period, with an adjusted EBITDA margin of 9.7%, up from 5.9%[8] - The company expects full year fiscal 2026 consolidated net sales to be between $295 million and $310 million, with Adjusted EBITDA between $30 million and $35 million[10] - For Q2 fiscal 2026, consolidated net sales are expected to be approximately $69 million, with Adjusted EBITDA of approximately $5 million[11] Sales and Unit Performance - MasterCraft's consolidated unit sales volume increased by 2.5% to 565 units in Q3 2025, compared to 551 units in Q3 2024[23] - Consolidated net sales rose by 5.6% to $69,002 thousand in Q3 2025, up from $65,359 thousand in Q3 2024[23] - The company reported a significant increase in pontoon unit sales by 6.2%, reaching 188 units in Q3 2025[23] Profitability Metrics - Gross margin percentage increased by 420 basis points during Q1 fiscal 2026, primarily due to increased net sales and effective cost controls[6] - Gross margin improved by 420 basis points to 22.3% in Q3 2025, compared to 18.1% in Q3 2024[23] - Adjusted EBITDA for Q3 2025 was $6,705 thousand, representing a margin of 9.7%, compared to $3,842 thousand and a margin of 5.9% in Q3 2024[31] - Adjusted Net Income increased to $4,532 thousand in Q3 2025, up from $1,938 thousand in Q3 2024[31] - Adjusted Net Income per diluted share rose to $0.28 in Q3 2025, compared to $0.12 in Q3 2024[32] - Income from continuing operations increased to $3,656 thousand in Q3 2025, up from $1,016 thousand in Q3 2024[31] Cash Flow and Shareholder Returns - Free cash flow for Q3 2025 was negative at $(10,127) thousand, compared to $(2,707) thousand in Q3 2024[32] - Share repurchases during the quarter amounted to $2.3 million[4] Strategic Initiatives - The company launched the new MasterCraft X24 model, enhancing brand excitement and momentum[3] - MasterCraft maintains a debt-free balance sheet, considered one of the strongest in the industry, allowing for confident investments throughout the cycle[3] Taxation - MasterCraft's income tax expense for fiscal 2026 reflects an income tax rate of 23.0%[33]

Exhibit 99.1 Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update BEDFORD, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2025. "Lantheus' third quarter results underscore the strength of our s ...

Exhibit 99.1 Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028 6 November 2025 • Completed enrollment in the SANRECO Phase 2 study of divesiran for the treatment of PV. The Phase 2 portion of SANRECO is a global, randomized, double-blind, placebo-controlled trial that enrolled 48 phlebotomy-dependent ...

EXHIBIT 99.1 REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights ROCKVILLE, Md., November 6, 2025 (PR Newswire) -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025. "The positive data and significant clinical milestones achieved across each of our late-stage programs underscore the meaningful progress we're making towards delivering potentially transformative gene therapies," said Curran M. ...

Revenue Performance - Revenue for the three months ended September 30, 2025, decreased by $720,000, or 44.8%, to $887,000 from $1.6 million in the same period of 2024, primarily due to a decline in service revenue from technology and services contracts [160]. - One customer accounted for 89% of total revenue for the three months ended September 30, 2025, compared to one customer accounting for 54% and another for 32% in the same period of 2024 [161]. - Revenue decreased by $0.1 million, or 3.5%, to $3.6 million for the nine months ended September 30, 2025, largely due to reduced service revenue from government and commercial contracts [170]. Operating Loss and Expenses - Operating loss for the three months ended September 30, 2025, was $19.9 million, compared to a loss of $13.9 million in the same period of 2024 [158]. - Selling, general and administrative expenses rose to $10 million for the three months ended September 30, 2025, compared to $8 million in the same period of 2024, driven by business growth and public company compliance costs [158]. - Research and development expenses increased to $5.2 million for the three months ended September 30, 2025, from $3.5 million in the same period of 2024, reflecting ongoing investment in PNT technologies [158]. - Selling, general and administrative expenses increased by $6.2 million, or 25.2%, to $30.8 million for the nine months ended September 30, 2025, primarily due to higher payroll-related and stock-based compensation expenses [174]. - Research and development expenses for the nine months ended September 30, 2025, increased by $1.7 million, or 13.7%, to $14.0 million, mainly due to higher non-recurring engineering services [173]. Cash Flow and Financing Activities - Net cash used in operating activities for the nine months ended September 30, 2025 was $34.7 million, compared to $26.1 million for the same period in 2024 [182][184]. - Net cash used in investing activities during the nine months ended September 30, 2025 was $35.0 million, up from $17.7 million in 2024 [185][186]. - Net cash provided by financing activities for the nine months ended September 30, 2025 was $120.1 million, significantly higher than $29.7 million in 2024 [187][188]. - The company entered into a Note Purchase Agreement to sell $190.0 million in 5% Senior Secured Convertible Notes due in 2028 [181]. - Cash proceeds from the issuance of the 2028 Notes were a primary contributor to the financing activities in 2025 [187]. Patents and Regulatory Changes - The company has been granted 165 patents related to its systems and services, enhancing its competitive position in the PNT market [141]. - The company signed an agreement to acquire an additional 4 MHz of M-LMS licenses, expanding its spectrum coverage to over 90% of the U.S. population [142]. - The company is pursuing regulatory changes to the Lower 900 MHz band to enable a 15 MHz nationwide spectrum configuration for both PNT and 5G broadband services [143]. Other Financial Metrics - Other income increased significantly to $23.6 million for the three months ended September 30, 2025, compared to $2.5 million in the prior year, primarily due to gains from changes in fair value of derivative liabilities [169]. - The company incurred net losses of $121.3 million for the nine months ended September 30, 2025, compared to $69.6 million in the prior year, with cash and cash equivalents totaling $167.6 million as of September 30, 2025 [179]. - The company reported a net loss of $121.3 million for the nine months ended September 30, 2025, compared to a net loss of $69.6 million in 2024 [183][184]. - Non-cash charges included $36.4 million for change in the fair value of derivative liability and $12.5 million for stock-based compensation in 2025 [183]. - The company experienced a net increase in operating liabilities of $5.7 million during the nine months ended September 30, 2025 [183]. Depreciation and Cost of Goods Sold - Cost of Goods Sold (COGS) decreased by $0.5 million, or 21.0%, to $2.0 million for the three months ended September 30, 2025, primarily due to reductions in payroll-related expenses and software license costs [162]. - COGS for the nine months ended September 30, 2025, decreased by $1.7 million, or 20.1%, to $6.6 million, driven by lower payroll-related and software license expenses [171]. - Depreciation and amortization expenses surged by $2.2 million, or 170.1%, to $3.5 million for the three months ended September 30, 2025, attributed to accelerated depreciation of retired network assets [166]. Market Risks - There were no material changes in market risks from those disclosed in the 2024 Form 10-K [191].

EXHIBIT 99 November 6, 2025 Cummins Reports Strong Third Quarter Operating Results, Records Non-Cash Charges Related to its Electrolyzer Business COLUMBUS, IND. - Cummins Inc. (NYSE: CMI) today reported results for the third quarter of 2025. "Cummins delivered strong operating results in the third quarter, driven by profitable growth in our Power Systems and Distribution segments, due in part to continued rising demand for backup power for datacenters. Effective cost management across the company helped nav ...

Portfolio Composition - As of September 30, 2025, the gross book value of the company's portfolio was comprised of 41% multi-family, 40% office, 11% hotels, 6% life science, and 2% mixed use and other[190]. - The top market by gross book value is Manhattan, accounting for 21% of the total, followed by Washington, DC at 10% and Boston at 8%[219]. - The portfolio is diversified with 41% in multifamily properties and 40% in office properties, indicating a balanced investment strategy[220]. Financial Performance - Total revenues for the three months ended September 30, 2025, were $96.2 million, an increase of $5.5 million compared to $90.7 million for the same period in 2024[226]. - For the nine months ended September 30, 2025, total revenues increased to $287.7 million from $273.8 million for the same period in 2024, representing a growth of 5.1%[242]. - Net income for the nine months ended September 30, 2025, was $86.7 million, compared to $80.5 million in 2024, marking an increase of 7.6%[242]. - Interest income from sales-type leases rose to $72.4 million for the three months ended September 30, 2025, up from $67.1 million in the same period in 2024, driven by new originations[228]. - Interest income from sales-type leases rose to $212.7 million for the nine months ended September 30, 2025, up from $195.6 million in 2024, an increase of 8.8%[242]. - Earnings from equity method investments decreased to $14.6 million for the nine months ended September 30, 2025, down from $18.1 million in 2024, a decline of 19.4%[254]. Expenses and Losses - General and administrative expenses for the three months ended September 30, 2025, were $13.1 million, slightly down from $13.1 million in the same period in 2024[235]. - The provision for credit losses for the nine months ended September 30, 2025, was $5.7 million, a decrease from $8.4 million in the same period of 2024, reflecting improved market conditions[252]. - Interest expense increased to $154.2 million for the nine months ended September 30, 2025, compared to $147.7 million in 2024, an increase of 4.0% due to higher indebtedness[247]. Liquidity and Capital Management - The company has a liquidity capacity of $1.1 billion under its 2024 Unsecured Revolver as of September 30, 2025, enhancing its financial flexibility[264]. - The company entered into a new $2.0 billion unsecured revolving credit facility in April 2024, replacing previous facilities and extending maturity to May 1, 2029[262]. - As of September 30, 2025, the company had $12.1 million of unrestricted cash and $1.1 billion of undrawn capacity on its 2024 Unsecured Revolver[266]. - The company expects to meet its liquidity requirements over the next 12 months through cash on hand, cash flows from operations, and unused borrowing capacity[267]. Investment Strategy - The company targets Ground Lease investments where the initial cost represents 30% to 45% of the Combined Property Value, indicating a strong correlation between inflation and commercial real estate values over time[198]. - The company identifies a significant market opportunity in the approximately $7.0 trillion institutional commercial property market in the U.S., aiming to expand the use of Ground Leases beyond current fragmented ownership[210]. - The company has initiated new products such as the Ground Lease Plus Fund and Leasehold Loan Fund to enhance its service offerings and capture more market share[211]. Risk Factors - The company has entered into a forbearance agreement with a tenant under a significant New York office asset, which poses risks of potential losses if the tenant defaults[194]. - The rise in interest rates has adversely affected the U.S. office sector, leading to increased vacancies and reduced market liquidity, which could negatively impact the company's tenants and property values[192]. - A 100 basis point increase in interest rates could result in a decrease in net income by approximately $3.994 million[280]. - The company aims to mitigate interest rate volatility through hedging instruments, including interest rate swap agreements[277]. Cash Flow Analysis - Cash flows provided by operating activities increased to $35.495 million for the nine months ended September 30, 2025, compared to $29.957 million in 2024[268]. - Cash flows used in investing activities decreased to $(180.185) million in 2025 from $(190.897) million in 2024, primarily due to a decrease in the origination of Ground Leases[268]. - Cash flows provided by financing activities increased to $148.831 million in 2025 from $138.462 million in 2024, driven by acquisition activities in 2024[268]. Shareholder Actions - The company authorized a share repurchase program of up to $50.0 million on February 4, 2025, allowing for strategic capital management[259]. - As of September 30, 2025, approximately 14.4% of the outstanding Caret units were beneficially owned by the company's officers and employees, with 128,971 Caret units remaining available for issuance under the Caret Performance Incentive Plan[208].

Financial Performance - Total Revenue for 9M 2025 increased by 10% to $43,236 million, with Product Sales up 9% and Alliance Revenue up 41%[6]. - Reported EPS for Q3 2025 rose by 77% to $1.64, while Core EPS increased by 15% to $7.04[6][17]. - Core Operating profit increased by 13% for 9M 2025, reflecting strong performance across all therapy areas[13]. - For the first nine months of 2025, Product Revenue reached $43,143 million, reflecting a 10% increase compared to the previous year[36]. - The profit for the period for Q3 2025 was $2,535 million, compared to $1,433 million in Q3 2024, indicating a significant increase of approximately 77%[126]. - Profit before tax for 9M 2025 was $9,773 million, a 39% increase from $7,025 million in 9M 2024[94]. - Total comprehensive income for the period was $10,156 million for the nine months ended September 30, 2025, compared to $6,352 million in 2024, showing a growth of approximately 59%[123]. - The operating profit for the nine months ended September 30, 2025, was $10,765 million, compared to $7,967 million in 2024, reflecting a year-over-year increase of about 35.5%[123]. - Earnings per share (EPS) rose by 43% to $5.10 in 9M 2025, compared to $3.57 in 9M 2024[92]. Revenue Breakdown - Oncology Product Revenue accounted for $18,590 million, representing 43% of total revenue, with a 16% increase year-over-year[38]. - The US market generated $18,517 million in revenue, contributing 43% to total revenue, with an 11% increase year-over-year[40]. - Imfinzi saw a revenue increase of 25% to $4,317 million, driven by strong growth in new indications for bladder and lung cancer[42]. - The introduction of new products like Beyfortus and Tezspire contributed significantly to Alliance Revenue, which totaled $2,108 million, up 41% year-over-year[36]. - Lynparza generated total revenue of $2,401 million in 9M 2025, reflecting an 8% increase compared to the previous year, with significant share gains in ovarian, breast, and prostate cancer indications[44][45]. - Enhertu sales reached $3,575 million in 9M 2025, a 31% increase from $2,729 million in 9M 2024, driven by strong demand in HER2-positive and HER2-low metastatic breast cancer[46][47]. - Farxiga's total revenue was $6,426 million in 9M 2025, an 11% increase, with strong growth in emerging markets despite generic competition[49]. - Beyfortus achieved total revenue of $474 million in 9M 2025, a 49% increase, driven by increased capacity and strong demand[59]. - Ultomiris generated $3,453 million in total revenue, a 22% increase, with significant growth in emerging markets and strong demand across various indications[61]. Research and Development - AstraZeneca's R&D pipeline includes ongoing clinical trials for 20 approved and potential new medicines, with over 160 abstracts presented at major medical congresses[68]. - The BaxHTN Phase III trial showed an absolute reduction in mean seated systolic blood pressure of 15.7 mmHg and a placebo-adjusted reduction of 9.8 mmHg for the 2mg dose of baxdrostat[72]. - The TULIP-SC trial demonstrated a statistically significant reduction in disease activity in patients with systemic lupus erythematosus compared to placebo[74]. - AstraZeneca presented 32 abstracts and 13 posters at the European Society of Cardiology (ESC) in Madrid, showcasing its commitment to cardiovascular research[71]. Strategic Initiatives - AstraZeneca is investing $50 billion in US manufacturing and R&D by 2030, with a new $4.5 billion manufacturing facility in Virginia expected to create approximately 3,600 jobs[20][21]. - A historic agreement with the US government aims to lower prescription medicine costs for American patients, aligning prices with those in wealthier countries[22]. - The Group anticipates continued growth in Product Revenue, driven by strong demand across key therapeutic areas and new product launches[35]. - The company plans to increase annual dividends per share to $3.20 in FY 2025, up from the previous levels, contingent on profit generation and subsidiary distributions[117]. - The company plans to announce FY and Q4 2025 results on February 10, 2026, indicating ongoing commitment to transparency and shareholder communication[175]. Acquisitions and Collaborations - AstraZeneca completed the acquisition of SixPeaks Bio AG for a total of up to $315 million, focusing on weight-management therapies[24]. - The updated agreement with Merck for Koselugo includes an upfront payment of $150 million and potential deferred payments totaling up to $400 million[25]. - EsoBiotec acquisition completed for $403m, including intangible assets of $426m and contingent consideration of up to $575m based on regulatory milestones[145]. Sustainability and Recognition - AstraZeneca was recognized by TIME Magazine as one of the World's Best Companies, ranking 43rd globally and first in the pharmaceutical sector for sustainability transparency[26]. - The Company secured fifth place in Sustainability Magazine's Top 250 World's Most Sustainable Companies 2025, affirming its leadership in responsible business[78]. - AstraZeneca's Young Health Programme received the ACE Award for Workforce Innovation and Global Impact, recognizing its role in advancing health equity and strengthening health systems[87]. Legal and Regulatory Matters - The company is involved in multiple legal proceedings, including a $97 million settlement related to Seroquel XR antitrust litigation[165]. - AstraZeneca prepaid RMB 24 million (approximately $3.5 million) in unpaid taxes related to Enhertu, Imfinzi, and Imjudo in China[164]. - The company filed lawsuits against multiple states in the US challenging the constitutionality of the 340B statute[165]. - AstraZeneca's challenge against the Inflation Reduction Act was dismissed by the US Court of Appeals, with a review sought by the US Supreme Court[165]. - The company is currently facing inquiries into drug marketing and pricing practices, with no material developments reported[166].